This study is carried out by Prof. Qiang Liu (Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University). In this study, researchers found that the palbociclib-resistant breast cancer ...

Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.

Tuojie Biotech (Shanghai) Co. Ltd. has prepared oxygen-containing fused tricyclic derivatives acting as CDK2/cyclin E1 and/or CDK4/cyclin D1 inhibitors. As such, they are reported to be potentially ...

An Allorion Therapeutics (Guangzhou) Co. Ltd. patent discloses aminoheteroaryl CDK4/cyclin D1 inhibitors reported to be useful for the treatment of cancer.

BUFFALO, NY- December 2, 2022 – A new review was published in Genes & Cancer on August 25, 2022, entitled, “CDK4: a master regulator of the cell cycle and its role in cancer.” The mammalian cell cycle ...

The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State We retrospectively analyzed a multi-institutional cohort of patients with ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today presented preclinical data related to the company’s cyclin ...

Cyclin D1 is overexpressed in certain solid tumors and hematologic malignancies. In these cancers, the cyclin D1/CDK4 complex drives cell proliferation by binding to the tumor suppressor ...